خط مشی دسترسیدرباره ما
ثبت نامثبت نام
راهنماراهنما
فارسی
ورودورود
صفحه اصلیصفحه اصلی
جستجوی مدارک
تمام متن
منابع دیجیتالی
رکورد قبلیرکورد بعدی
نوع مدرک : TF
زبان مدرک : فارسی
شماره رکورد : 66950
شماره مدرک : ‭پ۵۳۴۵۴‬
شماره راهنما : ‭ت۲۶۰۳‬
سر شناسه : حق بین، علی
عنوان اصلي : بررسی تاثیر تجویز سولفات روی بر بهبود پنومونی در کودکان‭ ۵۹-۲ ‬ماهه بستری در بخشهای اطفال بیمارستان های امام رضا(ع‭(‬ و قائم (عج‭(‬ و دکتر شیخ
نام عام مواد : [پایان‌نامه]
نام نخستين پديدآور : /علی حق بین
نام ساير پديدآوران : ؛استاد راهنما: فرهاد حیدریان، حمید آهنچیان
نام ساير پديدآوران : ؛استاد مشاور: سعید ابراهیم زاده
عنوان ديگر : عنوان به انگلیسی‭Evaluation of the effect of Zinc Sulfate on the improvement of clinical manifestations of pneumonia in hospitalized children agaed 2-59 months :‬
وضعيت نشر : دانشگاه علوم پزشکی مشهد، ‭۱۳۹۱‬، دانشکده پزشکی
صفحه شمار : ‮‭[۵۷]‬ ص.‬: جدول، نمودار
يادداشت : چکیده فارسی، چکیده انگلیسی
يادداشت : چاپی
خلاصه يا چکيده : ‭1391.They randomly divided into 2 groups :cases who take zinc sulfate and controls (54 patients) who take placebo(54 patients) . Zinc levels in serum was taken at admission and at discharge in both groups. Clinical features including tachypnea, fever, retractions and hypoxia were recorded every 12 hours.Results: Mean serum zinc levels in case group at admission and at discharge time was statistically significant but zinc sulfate has not any effect on reducing the lenght of hospitalization Tachypnea had significant difference after 36 hours in control group. Fever had significant difference after 24 and 36 in control group and cough had significant difference after 24 hours in control group. Conclusion: Zinc sulfate has not any effect on reducing the lenght of hospitalization -controlled clinical trial conducted between performed on 108 patients with , pneumonia aged 2 to 59 months who admit at pediatrics ward of Ghaem and Dr.sheikh hospital from 1390-blind, placebo-severe or severe pneumonia in children between 259 month of age. The present study was undertaken to find out the efficacy of zinc supplementation in the treatment of pneumonia, beside standard antimicrobial therapy, in hospitalized children, aged 2 to 59 months, by comparing the different outcome measures between zinc supplemented and placebo groups.Method:This study was a randomized, double-Introduction:Worldwide, pneumonia is the leading cause of pediatric morbidity and mortality. It is estimated that pneumonia is responsible for >1/9 million deaths each year in children below 5 years of age, and the younger age groups have the highest risk of death. Zinc supplementation lowers the risk of acute respiratory illnesses and diarrhea in children. we demonstrated that Zn neither reduced the risk of treatment failure nor hasten the recovery of non‬
 
 
 
(در صورت عدم وضوح تصویر اینجا را کلیک نمایید)